Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 110,842 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 110,842 shares of Phibro Animal Health stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the completion of the sale, the chief executive officer directly owned 122,958 shares in the company, valued at approximately $5,948,708.04. This represents a 47.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total transaction of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.

Phibro Animal Health Price Performance

PAHC opened at $51.85 on Tuesday. The firm has a 50-day moving average price of $40.32 and a 200-day moving average price of $38.59. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $56.30. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 0.82 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The company had revenue of $373.91 million for the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s payout ratio is presently 21.33%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in Phibro Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after buying an additional 21,951 shares in the last quarter. Prospera Financial Services Inc grew its position in Phibro Animal Health by 11.4% in the fourth quarter. Prospera Financial Services Inc now owns 26,999 shares of the company’s stock worth $1,009,000 after acquiring an additional 2,762 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Phibro Animal Health by 17.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 4,964 shares of the company’s stock valued at $185,000 after acquiring an additional 731 shares during the last quarter. 1620 Investment Advisors Inc. raised its position in Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares in the last quarter. Finally, Independent Advisor Alliance lifted its stake in Phibro Animal Health by 36.8% during the fourth quarter. Independent Advisor Alliance now owns 36,795 shares of the company’s stock worth $1,375,000 after purchasing an additional 9,900 shares during the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PAHC shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. JPMorgan Chase & Co. boosted their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.